Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. We strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer and inflammation, and serious respiratory and cardiovascular conditions. - See more at: http://www.gilead.com/about#sthash.rpDd6mCW.dpuf

Research Grants 28 show all


$12.3M
2013

$1.1M
2014

$5.3M
2015

$3.2M
2016

$1.1M
2018

Patents 9,609show all

  • 1,872
    A61K - Preparations for medical, dental, or toilet purposes
  • 1,507
    C07D - Heterocyclic compounds
  • 710
    C07H - Sugars
  • 453
    C07F - Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
  • 416
    C07K - Peptides
  • 396
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms
  • 390
    C12N - Microorganisms or enzymes
  • 363
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 197
    C07C - Acyclic or carbocyclic compounds
  • 193
    C40B - Combinatorial chemistry

Clinical Trials 1,811show all

536Phase 3422Phase 2416N/A138Phase 4122Phase 188Other

SEC Filings show all


229
8-K

72
10-Q

19
10-K

1
D

Contact Information

Foster City, CA
United States

SEC Form D Funding Events

DateOfferedSoldType
2006-04-03Unknown Unknown Other (Paper Filing)